Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F230 Phase I Study in Healthy Volunteers
NCT06899815Phase 1Recruiting
- Sponsor
- Gyre Pharmaceuticals
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of F230 in pulmonary hypertension (PH) (3 arms), sponsored by Gyre Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 48 hours, Time to Maximum Plasma Concentration at 48 hours and 2 more. Started May 2025; status: recruiting.
02
Drugs
F230
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT06899815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06899815.